Jeff Park Elected to Diplomat Board of Directors

FLINT, Mich., June 8, 2017 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), shareholders elected Mr. Park to its board of directors at today's annual shareholders meeting.

He will serve a three-year term as a Class III director.

Park served as chief operating officer for OptumRx, the pharmacy care services business of UnitedHealth Group, from July 2015 to July 2016 after OptumRx merged with pharmacy benefit manager (PBM) Catamaran Corporation. Park had been Catamaran's executive vice president of operations since March 2014 after becoming chief financial officer in 2006.

Before serving as chief financial officer, Park was a member of Catamaran's board of directors and a senior vice president of Covington Capital Corporation, a private equity venture capital firm, where he was responsible for assessing new business opportunities, negotiating and structuring transactions and advising investee companies. He has also worked for IBM in several areas of its Global Services Organization and as an audit manager with Deloitte Canada.

Park has held key managerial, financial, and operational responsibilities during his 11 years in the health care industry, playing a significant role in acquisitions and organic growth. He has extensive financial, accounting, and corporate governance experience.

"Jeff Park is an important addition to Diplomat's board of directors," said Phil Hagerman, CEO and chairman of Diplomat. "He has substantial experience in the PBM industry, a field significant to our business. Our board believes Jeff's broad experience across important industries will add a valuable perspective to our growth strategy."

Ben Wolin, Diplomat's independent lead director, added, "We are enthusiastic about Jeff Park joining as a director and look forward to benefitting from his judgement, counsel, and unique expertise.

"I'm honored to begin working more closely with my fellow board members," Park said. "Diplomat does an incredible job putting the patients first as the largest independent provider of specialty pharmacy services. I'm excited to work with a company that has maintained personal care on a national level."

To learn more about Diplomat, visit diplomat.is.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended Dec. 31, 2016, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.

About Diplomat

Diplomat (NYSE: DPLO) is the nation's largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payors, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.

INVESTOR CONTACT:
Bob East, Westwicke Partners
443.213.0500 | [email protected]

MEDIA CONTACT:
Jenny Cretu, Diplomat
810.768.9370 | [email protected]

SOURCE Diplomat Pharmacy, Inc.

Related Links

http://www.diplomat.is

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED